Showing results (111-120 of 206) with videos related to

Sort By:
Pageof 21
Prostate Cancer and Prostatic Diseases|July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitorsGeorges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers|October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United StatesUmang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumabGeorges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
The Oncologist|August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy ResultsBenjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Therapeutic Advances in Urology|November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolixPatrick Campbell, Georges Gebrael, Arshit Narang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2025
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell CarcinomaYousef Zakharia, Ryan J Reis, Matthew R Kroll, et al.
Urologic Oncology|August 2, 2022
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinomaNishita Tripathi, Yeonjung Jo, Abhishek Tripathi, et al.
JNCI Cancer Spectrum|January 30, 2025
A novel machine learning-based cancer-specific cardiovascular disease risk score among patients with breast, colorectal, or lung cancerNickolas Stabellini, Omar M Makram, Harikrishnan Hyma Kunhiraman, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
Pageof 21